Holko Przemysław, Kawalec Paweł, Stawowczyk Ewa
Department of Drug Management, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):456-464. doi: 10.1097/MEG.0000000000001047.
Inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn's disease (CD) are chronic autoimmune disorders that constitute a major societal and economic burden for individual patients, their families and the society. The aim of this study was to assess the current prevalence and treatment patterns of IBD in Poland.
We carried out a retrospective analysis of the nationwide databases of the National Health Fund for the years from 2012 to 2014 to obtain data on the prevalence and treatment patterns of IBD. Patients with IBD were identified according to the ICD-10 codes indicated in medical records and the type of medical resource utilized during the study. Pharmacotherapy for IBD by age group, sex and IBD types was presented.
The prevalence of IBDs was 157/100 000 individuals, including 35 patients with CD per 100 000 individuals. The use of drugs differed by age and diagnosis (P<0.001). Biologics, steroids and immunosuppressants were used more often by patients with CD than those with UC (13.2 vs. 0.3%, 54.5 vs. 37.5%, and 44.8 vs. 15.1%, respectively). Aminosalicylates were used more often by patients with UC than those with CD. Biologics were used most often by the youngest patients (≤18 years) and seldom by patients aged 65 years or older (7.7 and 0.1%, respectively).
Our study showed a moderate prevalence of IBD in Poland. Treatment patterns depended on the patient's age and IBD type. The use of biologics was higher among young patients with CD than among older patients with other IBDs. Although not recommended, aminosalicylates were still commonly used in patients with CD, even during biologic and/or immunosuppressive treatment.
炎症性肠病（IBD），如溃疡性结肠炎（UC）和克罗恩病（CD），是慢性自身免疫性疾病，给患者个体、其家庭和社会带来了重大的社会和经济负担。本研究的目的是评估波兰IBD的当前患病率和治疗模式。
我们对2012年至2014年国家卫生基金的全国性数据库进行了回顾性分析，以获取IBD患病率和治疗模式的数据。根据病历中所示的国际疾病分类第十版（ICD - 10）编码以及研究期间所使用的医疗资源类型来确定IBD患者。按年龄组、性别和IBD类型呈现了IBD的药物治疗情况。
IBD的患病率为每100,000人中有157例，其中每100,000人中有35例CD患者。药物使用情况因年龄和诊断而异（P<0.001）。与UC患者相比，CD患者更常使用生物制剂、类固醇和免疫抑制剂（分别为13.2%对0.3%、54.5%对37.5%、44.8%对15.1%）。UC患者比CD患者更常使用氨基水杨酸类药物。生物制剂在最年轻的患者（≤18岁）中使用最为频繁，而在65岁及以上的患者中很少使用（分别为7.7%和0.1%）。
我们的研究表明波兰IBD的患病率处于中等水平。治疗模式取决于患者的年龄和IBD类型。年轻的CD患者比患有其他IBD的老年患者更常使用生物制剂。尽管不推荐，但氨基水杨酸类药物在CD患者中仍普遍使用，即使在生物制剂和/或免疫抑制治疗期间也是如此。
